{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:59:29Z","timestamp":1793725169821,"version":"4.6.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.xcrm.2024.101751","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T10:33:24Z","timestamp":1727778804000},"page":"101751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Thymosin \u03b11 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy"],"prefix":"10.1016","volume":"5","author":[{"given":"Kua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingkai","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huawei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilei","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciliang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4753-2648","authenticated-orcid":false,"given":"Junhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101751_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2024.101751_bib2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.cell.2019.01.008","article-title":"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization","volume":"176","author":"Sanmamed","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101751_bib3","article-title":"Clinical cancer immunotherapy: Current progress and prospects","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101751_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.xcrm.2024.101751_bib5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd.2016.178","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"15","author":"Kaufman","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2024.101751_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ebiom.2018.04.020","article-title":"Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy","volume":"31","author":"Achard","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2024.101751_bib7","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2024.101751_bib8","article-title":"Systematic review of combinations of targeted or immunotherapy in advanced solid tumors","volume":"9","author":"Tan","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2024.101751_bib9","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1128\/JVI.02372-13","article-title":"Adenovirus E1B 19-kilodalton protein modulates innate immunity through apoptotic mimicry","volume":"88","author":"Radke","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101751_bib10","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2019.07.019","article-title":"Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1\/CD137L Subverts the Suppression of CD8(+) T Cells in HCC","volume":"27","author":"Zhang","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101751_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202103470","article-title":"An Inter-Supplementary Biohybrid System Based on Natural Killer Cells for the Combinational Immunotherapy and Virotherapy of Cancer","volume":"9","author":"Ding","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xcrm.2024.101751_bib12","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1021\/acs.nanolett.9b00145","article-title":"Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy","volume":"19","author":"Lv","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.xcrm.2024.101751_bib13","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.1021\/acsnano.6b06182","article-title":"Oncolytic Adenovirus Complexes Coated with Lipids and Calcium Phosphate for Cancer Gene Therapy","volume":"10","author":"Chen","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.xcrm.2024.101751_bib14","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101751_bib15","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.xcrm.2024.101751_bib16","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101751_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3233\/CBM-181286","article-title":"Recombinant adenovirus p53 combined with radiotherapy improves efficacy and safety in the treatment of head and neck lymphoma","volume":"23","author":"Xu","year":"2018","journal-title":"Cancer Biomarkers"},{"key":"10.1016\/j.xcrm.2024.101751_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.2012.06707.x","article-title":"Thymosin alpha1 as a stimulatory agent of innate cell-mediated immune response","volume":"1270","author":"Serafino","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.xcrm.2024.101751_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14712598.2018.1456527","article-title":"Potential mechanism of thymosin-alpha1-membrane interactions leading to pleiotropy: experimental evidence and hypotheses","volume":"18","author":"Mandaliti","year":"2018","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.xcrm.2024.101751_bib20","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1158\/0008-5472.CAN-21-4260","article-title":"Thymosin alpha-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis","volume":"82","author":"Wei","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101751_bib21","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nm.3848","article-title":"Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity","volume":"21","author":"Ilkow","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101751_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41417-018-0042-1","article-title":"Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference","volume":"26","author":"Dyer","year":"2019","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.xcrm.2024.101751_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126526","article-title":"Tumor-Associated Macrophages as Multifaceted Regulators of Breast Tumor Growth","volume":"22","author":"Munir","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2024.101751_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2024.101751_bib25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","article-title":"Human FOXP3(+) Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer","volume":"50","author":"Wing","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2024.101751_bib26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/bs.vh.2016.04.003","article-title":"Immune Modulation with Thymosin Alpha 1 Treatment","volume":"102","author":"King","year":"2016","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.xcrm.2024.101751_bib27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2013.05.006","article-title":"The in\u00a0vivo immunomodulatory and synergistic anti-tumor activity of thymosin alpha1-thymopentin fusion peptide and its binding to TLR2","volume":"337","author":"Li","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2024.101751_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2024.101751_bib29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.xcrm.2024.101751_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2968","article-title":"Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47\u00a0antibody is an efficacious treatment for malignant pediatric brain tumors","volume":"9","author":"Gholamin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101751_bib31","article-title":"Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review","volume":"8","author":"Lecoultre","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2024.101751_bib32","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2024.101751_bib33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2024.101751_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2018.04.004","article-title":"IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets","volume":"41","author":"Unver","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.xcrm.2024.101751_bib35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1471-4906(03)00139-X","article-title":"PI3K and negative regulation of TLR signaling","volume":"24","author":"Fukao","year":"2003","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2024.101751_bib36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","article-title":"Signaling pathways of chronic kidney diseases, implications for therapeutics","volume":"7","author":"Yuan","year":"2022","journal-title":"Signal Transduct Tar"},{"key":"10.1016\/j.xcrm.2024.101751_bib37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev-immunol-101921-045939","article-title":"TGF-\u03b2 Regulation of T Cells","volume":"41","author":"Chen","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101751_bib38","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1172\/JCI80006","article-title":"Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages","volume":"125","author":"Ugel","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101751_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101751_bib40","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fonc.2019.01512","article-title":"Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice","volume":"9","author":"Jayasingam","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2024.101751_bib41","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Lawrence","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101751_bib42","article-title":"Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer","volume":"10","author":"Xu","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2024.101751_bib43","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13402-019-00453-z","article-title":"Tumor-associated macrophages: role in cancer development and therapeutic implications","volume":"42","author":"Salmaninejad","year":"2019","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.xcrm.2024.101751_bib44","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1517\/14712598.2015.1033393","article-title":"Historical review of thymosin alpha 1 in infectious diseases","volume":"15 Suppl 1","author":"Camerini","year":"2015","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.xcrm.2024.101751_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T\u00a0cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101751_bib46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","article-title":"Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy","volume":"26","author":"Kishton","year":"2017","journal-title":"Cell Metabol."},{"key":"10.1016\/j.xcrm.2024.101751_bib47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1749-6632.2010.05482.x","article-title":"Thymosin alpha 1: past clinical experience and future promise","volume":"1194","author":"Tuthill","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.xcrm.2024.101751_bib48","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s12272-001-2132-z","article-title":"Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization","volume":"31","author":"Gao","year":"2008","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.xcrm.2024.101751_bib49","doi-asserted-by":"crossref","first-page":"10374","DOI":"10.1021\/acsomega.0c00220","article-title":"Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in\u00a0Vivo","volume":"5","author":"Peng","year":"2020","journal-title":"ACS Omega"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124004816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124004816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T22:23:40Z","timestamp":1730586220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124004816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2666379124004816"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101751","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thymosin \u03b11 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101751"}}